Alpha Cognition Inc C.ACOG

Alternate Symbol(s): ACOG

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

CSE:ACOG - Post by User

Alpha Cognition Inc

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Dec 07, 2021 1:07pm

143 Views

Post# 34206960

$ACOG in the green after successful animal trials of A-1062

Alpha Cognition ( $ACOGF $ACOG.V) is up almost 13% after releasing promising experiment results yesterday.

The biotech company, which is developing drugs to help with neurodegenerative disorders, reported that their Alpha-1062 drug was very effective in treating animals with traumatic brain injuries (TBI).

ALPHA-1062 has already been shown to help with the effects of Alzheimer's.

However, this new study found that Alpha-1062 also reduced the extent of functional deficits, and improved functional recovery of animals with TBI so effectively that in most functional measures of recovery, the treated animals were statistically indistinguishable from uninjured animals.

Considering that 69M people get a TBI each year, Alpha-1062 could become a global medical game-changer if its efficacy translates to human patients.

$ACOG at $1.05/share

Full press release: https://finance.yahoo.com/news/alpha-cognition-announce-data-pre-140000753.html

TBI epidemiology source: https://thejns.org/view/journals/j-neurosurg/130/4/article-p1080.xml

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario